Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627498 | 0.83 | CYP4F2 (0.40) | DUT | |
| SCHEMBL1247083 | 0.83 | CYP4F2 (0.37) | DUT | |
| SCHEMBL17398452 | 0.82 | IDO1 (0.47) | MAOBMAOADUTSIGMAR1IDO1 | |
| SCHEMBL30879271 | 0.81 | TSHR (0.59) | MAOBTSHR | |
| SCHEMBL17760802 | 0.80 | IDO1 (0.46) | SIGMAR1IDO1 | |
| SCHEMBL16307320 | 0.80 | IDO1 (0.46) | SIGMAR1IDO1 | |
| SCHEMBL631424 | 0.80 | MAOB (0.42) | MAOBMAOACYP19A1ABHD6IDO1 | |
| SCHEMBL6558611 | 0.80 | IDO1 (0.46) | SIGMAR1IDO1 | |
| SCHEMBL16784080 | 0.80 | IDO1 (0.46) | SIGMAR1IDO1 | |
| SCHEMBL1246141 | 0.80 | DUT (0.37) | MAOBMAOADUTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20070135490-A1 | Phenetanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1675821-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| WO-2005044787-A1 | PHENETANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | WO | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | MAOB 371/4885MAOA 277/4885CYP19A1 4202/4885 |
| US-20070135490-A1 | Phenetanolamine derivatives | ADRB2, ADRB1, ADRB3 | MAOB 217/4885MAOA 136/4885CYP19A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.